Arbutus Biopharma's worrying high P/S ratio is underscored by its falling revenue. Investors could pay a steep premium as these declines might significantly affect the stock's value.
The Court of Appeals for the Federal Circuit (CAFC) just issued it's Mandate in connection with$Moderna(MRNA.US)$'s unsuccessful appeal of the '069 patent's validity. So the CAFC is now done with the case. Good news for$Arbutus Biopharma(ABUS.US)$.
$Moderna(MRNA.US)$'s deadline for filing a petition for rehearing at the Federal Circuit for the '069 patent case (no. 20-2329) passed last night, without any filing by MRNA. This is good for$Arbutus Biopharma(ABUS.US)$and $ROLV
Mcsnacks H Tupack樓主 : 無阻力